Johnson & Johnson (JNJ) Current Ratio: 1.03
Is Johnson & Johnson’s current ratio high or low?
Johnson & Johnson's current ratio of 1.03 is in line with its 5-year average of 1.14, near the low end of its 5-year range (0.99–1.35).
As of Thursday, June 11, 2026. 3.74% below its 12-month average of 1.07.
JNJ Current Ratio Chart
JNJ Average Current Ratio Chart
JNJ Current vs Average Current Ratio Chart
JNJ Current Ratio Metrics
CURRENT RATIO
1.03
CURRENT RATIO AVG TTM
1.07
CURRENT RATIO AVG 3Y
1.07
CURRENT RATIO AVG 5Y
1.14
CURRENT RATIO AVG 10Y
1.42
CURRENT RATIO AVG 15Y
1.66
CURRENT RATIO AVG 20Y
1.68
CURRENT VS TTM AVG
-3.74%
CURRENT VS 3Y AVG
-3.96%
CURRENT VS 5Y AVG
-9.78%
CURRENT VS 10Y AVG
-27.51%
CURRENT VS 15Y AVG
-37.86%
CURRENT VS 20Y AVG
-38.53%
JNJ Competitors' Current Ratio
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | $577.73B | 1.03 | 1.07 | 1.07 | 1.14 |
| Pfizer Inc. (PFE) | $149.61B | 1.16 | 1.17 | 1.11 | 1.20 |
| Merck & Co., Inc. (MRK) | $298.23B | 1.54 | 1.45 | 1.41 | 1.32 |
| AbbVie Inc. (ABBV) | $399.86B | 0.67 | 0.67 | 0.79 | 0.80 |
| Eli Lilly and Company (LLY) | $1.10T | 1.58 | 1.36 | 1.18 | 1.22 |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 1.26 | 1.25 | 1.30 | 1.38 |
Liquidity Analysis
Current Ratio
1.03
Quick Ratio
0.77
Johnson & Johnson Current Ratio Formula & Definition
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson Current Ratio FAQ
- What is the current ratio for Johnson & Johnson (JNJ)?
- The current ratio for JNJ stock is 1.03.
- Is Johnson & Johnson's current ratio high or low?
- Johnson & Johnson's current ratio of 1.03 is in line with its 5-year average of 1.14, near the low end of its 5-year range (0.99–1.35).
- What is the TTM average current ratio for Johnson & Johnson (JNJ)?
- The TTM average current ratio for JNJ stock is 1.07.
- What is the 3Y average current ratio for Johnson & Johnson (JNJ)?
- The 3Y average current ratio for JNJ stock is 1.07.
- What is the 5Y average current ratio for Johnson & Johnson (JNJ)?
- The 5Y average current ratio for JNJ stock is 1.14.
- What is the 10Y average current ratio for Johnson & Johnson (JNJ)?
- The 10Y average current ratio for JNJ stock is 1.42.
- What is the 15Y average current ratio for Johnson & Johnson (JNJ)?
- The 15Y average current ratio for JNJ stock is 1.66.
- What is the 20Y average current ratio for Johnson & Johnson (JNJ)?
- The 20Y average current ratio for JNJ stock is 1.68.
Johnson & Johnson Current Ratio History
| DATE | CURRENT RATIO |
|---|---|
| 2025-12-28 | 1.03 |
| 2024-12-29 | 1.11 |
| 2023-12-31 | 1.16 |
| 2023-01-01 | 0.99 |
| 2022-01-02 | 1.35 |
| 2021-01-03 | 1.21 |
| 2019-12-31 | 1.26 |
| 2018-12-31 | 1.47 |
| 2017-12-31 | 1.41 |
| 2016-12-31 | 2.47 |
| 2015-12-31 | 2.17 |
| 2014-12-31 | 2.36 |
| 2013-12-31 | 2.20 |
| 2012-12-31 | 1.90 |
| 2011-12-31 | 2.38 |
| 2010-12-31 | 2.05 |
| 2009-12-31 | 1.82 |
| 2008-12-31 | 1.65 |
| 2007-12-31 | 1.51 |
| 2006-12-31 | 1.20 |
| 2005-12-31 | 2.49 |
| 2004-12-31 | 1.96 |
| 2003-12-31 | 1.71 |
| 2002-12-31 | 1.68 |
| 2001-12-31 | 2.30 |
| 2000-12-31 | 2.30 |
| 1999-12-31 | 1.77 |
| 1998-12-31 | 1.39 |
| 1997-12-31 | 2.00 |
| 1996-12-31 | 1.81 |
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato